Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL1302633 | 0.95 | CA5A (0.60) | CA5ACA5BTSHRMEN1ALDH1A1 | |
| Sulfuric Acid SCHEMBL8579405 | 0.95 | CA5A (0.60) | CA5ACA5BTSHRMEN1ALDH1A1 | |
| Sulfuric Acid SCHEMBL2015466 | 0.95 | CA5A (0.60) | CA5ACA5BTSHRMEN1ALDH1A1 | |
| Sulfuric Acid SCHEMBL2141691 | 0.91 | CA5A (0.55) | CA5ACA5BTSHRMEN1ALDH1A1 | |
| Sulfuric Acid SCHEMBL9184498 | 0.91 | CA5A (0.55) | CA5ACA5BTSHRMEN1ALDH1A1 | |
| Sulfuric Acid SCHEMBL6843855 | 0.91 | CA5A (0.55) | CA5ACA5BTSHRMEN1ALDH1A1 | |
| Sulfuric Acid SCHEMBL21332424 | 0.91 | TSHR (0.67) | CA5ACA5BTSHRMEN1ALDH1A1 | |
| Sulfuric Acid SCHEMBL649359 | 0.91 | CA5A (0.55) | CA5ACA5BTSHRMEN1ALDH1A1 | |
| Sulfuric Acid SCHEMBL7159323 | 0.91 | TSHR (0.67) | CA5ACA5BTSHRMEN1ALDH1A1 | |
| Sulfuric Acid SCHEMBL10427546 | 0.91 | CA5A (0.55) | CA5ACA5BTSHRMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105008364-B | substituted Imidazopyridazines | 拜耳制药股份公司 | 2017-11-07 | — | — | CN | disclosed |
| EP-2961752-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-9512130-B2 | Substituted imidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| EP-3007698-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-20160016959-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-21 | — | — | US | disclosed |
| EP-2961752-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-06 | — | — | EP | disclosed |
| CN-105008364-A | Substituted imidazopyridazines | Bayer Pharma AG | 2015-10-28 | — | — | CN | disclosed |
| WO-2014198776-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014131739-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014020041-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-06 | — | — | WO | disclosed |
| US-5977074-A | THERAPY FOR ALZHEIMER'S DISEASE | MERRELL PHARMACEUTICALS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BUB1, BUB1B, CDK1 | CA5A 1351/4885CA5B 2084/4885TSHR 3185/4885 |
| US-20160016959-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | VEGFA, PGF, VHL | CA5A 253/4885CA5B 621/4885TSHR 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.